Pacer Advisors Inc. Sells 408 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Pacer Advisors Inc. reduced its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 0.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 65,490 shares of the biotechnology company’s stock after selling 408 shares during the quarter. Pacer Advisors Inc.’s holdings in Exelixis were worth $2,181,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of EXEL. USA Financial Formulas bought a new stake in shares of Exelixis during the fourth quarter valued at approximately $32,000. V Square Quantitative Management LLC bought a new stake in shares of Exelixis in the 3rd quarter worth $30,000. UMB Bank n.a. raised its stake in shares of Exelixis by 68.4% in the fourth quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 553 shares during the last quarter. Brooklyn Investment Group purchased a new position in shares of Exelixis in the third quarter worth $42,000. Finally, MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Exelixis by 18.1% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company’s stock valued at $63,000 after purchasing an additional 290 shares in the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on EXEL shares. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Exelixis in a research report on Monday, January 27th. TD Cowen increased their price objective on shares of Exelixis from $27.00 to $34.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Brookline Capital Management began coverage on shares of Exelixis in a report on Monday, December 23rd. They issued a “buy” rating on the stock. BMO Capital Markets lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and boosted their target price for the company from $36.00 to $40.00 in a research note on Friday, December 20th. Finally, Stephens restated an “equal weight” rating and issued a $29.00 price target on shares of Exelixis in a research note on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $36.06.

Insider Buying and Selling at Exelixis

In other Exelixis news, EVP Jeffrey Hessekiel sold 60,000 shares of the stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the completion of the sale, the executive vice president now directly owns 486,059 shares of the company’s stock, valued at $17,823,783.53. This trade represents a 10.99 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Patrick J. Haley sold 41,588 shares of the business’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $34.36, for a total transaction of $1,428,963.68. Following the completion of the transaction, the executive vice president now directly owns 288,665 shares in the company, valued at $9,918,529.40. This trade represents a 12.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 208,574 shares of company stock valued at $7,376,374 over the last ninety days. 2.85% of the stock is currently owned by company insiders.

Exelixis Trading Up 0.7 %

NASDAQ EXEL opened at $33.15 on Friday. Exelixis, Inc. has a 12 month low of $20.01 and a 12 month high of $37.59. The stock has a market cap of $9.47 billion, a price-to-earnings ratio of 21.25, a PEG ratio of 0.72 and a beta of 0.53. The company’s 50 day moving average is $34.68 and its two-hundred day moving average is $30.08.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.36 by $0.04. The firm had revenue of $539.50 million for the quarter, compared to the consensus estimate of $490.31 million. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The company’s revenue was up 14.3% on a year-over-year basis. During the same period last year, the firm earned $0.10 EPS. Sell-side analysts forecast that Exelixis, Inc. will post 1.74 EPS for the current year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.